Featured Topics
Calendar
Press Releases
Share Price / Index
February 05, 2026
Not intended for U.S. and UK Media – International Stroke Conference (ISC) 2026:
Bayer’s asundexian demonstrated a substantial, 26 percent reduction in stroke after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack with no increase in ISTH major bleeding versus placebo
February 03, 2026
Not intended for U.S. and UK Media
Nubeqa™ (darolutamide) receives third approval in China for men with advanced prostate cancer
January 30, 2026
Not intended for U.S. and UK Media
Finerenone recommended for the treatment of patients with heart failure with LVEF ≥40% in the EU

Our Products

Our broad product portfolio includes many world-famous brands that have shaped our Bayer brand. With our products, we are helping to find solutions to some of the greatest challenges of our time. So that health and nutrition can be made available to everyone.